Quantcast
Last updated on April 19, 2014 at 8:45 EDT

Latest neutropenia Stories

2012-12-12 16:23:33

PALO ALTO, Calif., Dec. 12, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced today the publication of a clinical trial abstract in the proceedings of the 54(th) Annual Meeting of the American Society of Hematology in Atlanta, Georgia. The abstract, "Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, for Treatment of Patients with Myeloid Growth Factor-Resistant Idiopathic Chronic Neutropenia (ICN)," by Roger M. Lyons, MD; Sharon T. Wilks, MD;...

2012-12-07 08:24:49

SAN ANTONIO, Dec. 7, 2012 /PRNewswire/ -- Results from the first large, global Phase III study of Halaven(®) (eribulin mesylate) Injection in patients with early-stage metastatic breast cancer were presented today during the 2012 CTRC-AACR San Antonio Breast Cancer Symposium. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) The 1,102-patient, open-label, multi-center study compared Halaven versus capecitabine (Xeloda(®)) in women with locally advanced or metastatic...

2012-11-28 12:26:49

WOODCLIFF LAKE, N.J., Nov. 28, 2012 /PRNewswire/ -- Eisai Inc. announced today that six abstracts highlighting new study results will be presented during the 2012 CTRC-AACR San Antonio Breast Cancer Symposium. The meeting will be held December 4-8, 2012 at the Henry B. Gonzalez Convention Center in San Antonio, TX. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) These studies highlight Eisai's current and ongoing clinical research efforts with Halaven(®) (eribulin...

2012-08-21 06:27:31

WASHINGTON and BERLIN, Aug. 21, 2012 /PRNewswire-USNewswire/ -- Although parents should be the protectors of their children, they can also be their most severe abusers. This seems to be the case in the life of Ariana-Leilani King-Pfeiffer, a 9-year-old dual German/American Citizen whose father is denying her access to medication that would save her life. The child has been diagnosed with severe chronic neutropenia (SCN), a life-threatening disease affecting only one in one million people...

2012-07-09 14:23:20

WOODCLIFF LAKE, N.J., July 9, 2012 /PRNewswire/ -- Eisai Inc. today announced preliminary results from a recently completed phase III study of Halaven versus capecitabine (Xeloda®) in women with locally advanced or metastatic breast cancer. The trial did not meet the pre-specified criteria for either of the co-primary endpoints of overall survival (OS) and progression-free survival (PFS). The study did show, however, a trend toward improved OS for patients who received Halaven compared...

2012-05-17 10:25:58

WOODCLIFF LAKE, N.J., May 17, 2012 /PRNewswire/ -- Eisai announced today that 15 abstracts highlighting new study results will be presented during the 48(th) Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from June 1 to June 5, 2012. These studies highlight Eisai's current product portfolio and oncology pipeline, reinforcing the company's commitment to patients and their families affected by cancer. "Our human health care mission is to help...

2011-11-03 08:00:00

PALO ALTO, Calif., Nov. 3, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced the publication in the Journal of Hematology & Oncology of: Oral ezatiostat HCl (Telintra®, TLK199) and Idiopathic Chronic Neutropenia (ICN): A case report of complete response of a patient with G-CSF resistant severe chronic idiopathic neutropenia following treatment with Telintra; Roger M. Lyons, MD et al. from the Cancer Care Centers of South Texas; Journal of Hematology...

2011-10-25 06:00:00

Greater attention to infection prevention is needed for vulnerable population ATLANTA, Oct. 25, 2011 /PRNewswire-USNewswire/ -- Each year more than one million patients receive cancer treatment in an outpatient oncology clinic. Despite advances in oncology care, infections from both community and health care settings remain a major cause of hospitalization and death among cancer patients receiving chemotherapy. To help protect this vulnerable patient population, the Centers for Disease...

2011-04-05 07:00:00

PALO ALTO, Calif., April 5, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today presented data at the 102nd American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida on a group of second generation analogs of ezatiostat, the most clinically advanced product in development at Telik. Ezatiostat is the first inhibitor of glutathione-S-transferase P1-1 (GST P-1), a validated enzyme target in Myelodysplastic Syndrome (MDS), to successfully complete a Phase 2 clinical...

2011-02-17 11:28:00

WASHINGTON and BERLIN, Feb. 17, 2011 /PRNewswire-USNewswire/ -- President Obama and Chancellor Merkel, "I don't want to die now!" is the urgent plea to two world-leaders from a child who will die without immediate medical intervention and protection. Ariana-Leilani King-Pfeiffer, a seven year old American and German citizen (with only a German passport) looks like any child. Yet she is very ill with a life-threatening very rare blood disorder called Severe Chronic Neutropenia. She is one of...